Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CFB | P00751 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3890373 | 0.87 | DRD2 (0.42) | KDM1ADRD2DRD4CFBOPRM1 | |
| SCHEMBL3901486 | 0.81 | NPC1 (0.45) | KDM1ANPC1RAB9ACFBOPRM1 | |
| SCHEMBL3894098 | 0.78 | NPC1 (0.47) | NPC1RAB9ACFB | |
| SCHEMBL3893608 | 0.76 | NPC1 (0.40) | DRD2DRD4NPC1RAB9ACFB | |
| SCHEMBL11399626 | 0.75 | NPC1 (0.48) | KDM1ANPC1RAB9ACFB | |
| SCHEMBL3893163 | 0.74 | GBA1 (0.43) | KDM1ANPC1RAB9ACFBOPRM1 | |
| SCHEMBL3890390 | 0.72 | SLC18A3 (0.45) | KDM1ADRD2DRD4NPC1RAB9A | |
| SCHEMBL3897588 | 0.70 | SCN9A (0.41) | DRD2OPRM1OPRD1OPRK1 | |
| SCHEMBL3892596 | 0.69 | DRD2 (0.44) | KDM1ADRD2DRD4OPRM1OPRD1 | |
| SCHEMBL3893429 | 0.68 | DRD2 (0.49) | DRD2DRD4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498344-B2 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| EP-0867183-B1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-10-06 | — | — | EP | disclosed |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. | 2004-09-23 | — | — | US | disclosed |
| US-6706734-B2 | ANTIISCHEMIC AGENTS; ANTICONVULSANTS; HEADACHES | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6455549-B1 | ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIMIGRAINE AGENTS; CALCIUM OVELOAD SUPPRESSANTS | SUNTORY LIMITED (JP) | 2002-09-24 | — | — | US | disclosed |
| EP-0867183-A1 | ARYLPIPERIDINOL AND ARYLPIPERIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130312-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | KDM1A 477/4885DRD2 2055/4885DRD4 3344/4885 |
| US-20040186138-A1 | Arylpiperidinol and arylpiperidine derivatives and pharmaceuticals containing the same | KCNH1, KCNH2, NPY1R | KDM1A 477/4885DRD2 2055/4885DRD4 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.